Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib Plus Docetaxel in PD-1 Inhibitor Experienced Patients With Incurable Head and Neck Squamous Cell Carcinoma
NCT05057247Phase 2Completed
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of duvelisib in squamous cell carcinoma of the head and neck (HNSCC). Started Oct 2021; status: completed.
02
Drugs
duvelisib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05057247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057247.